REVOLADE (eltrombopag), thrombopoietin receptor agonist
HAEMATOLOGY - New indication
Opinions on drugs - Posted on Nov 10 2016
Reason for request
Extension of indication
Minor improvement in the treatment of acquired severe aplastic anaemia refractory and ineligible for stem-cell transplantation
- REVOLADE now has Marketing Authorisation in the treatment of adults with acquired severe aplastic anaemia who are either refractory to prior immunosuppressive therapy or heavily pretreated and who are ineligible for haematopoietic stem-cell transplantation.
- In the absence of survival data, this treatment is non-curative. It does nevertheless represent a minor improvement in treatment this new indication.
Clinical Added Value
Évaluation des médicaments